There’s new hope for the flailing SPAC market.
The merger last week between the blank-check company Frazier Lifesciences Acquisition Corp. and the clinical-stage biopharma company NewAmsterdam Pharma Holding appears to be in much better financial shape than the usual post-SPAC deal these days.
Just